Public-domain · open source
OpenJurist
← 593 F.3d 428 - Demahy v. Actavis, Inc.

Demahy v. Actavis, Inc.’s Empirical Analysis

593 F.3d 428 · 2010

Citation profile

31
cited by 31 later decisions
3
cited 3 times by the Supreme Court
2
states following
March 2017
most recently cited

7 federal appellate · 5 district · 3 state decisions

Relationships

Applies 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 356A (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 379R (Federal Food, Drug, and Cosmetic Act)

Relies on Rice v. Santa Fe Elevator Corp. · Florida Lime & Avocado Growers, Inc. v. Paul · Medtronic, Inc. v. Lohr · Fidelity Federal Savings and Loan Association v. D Cuesta · Food & Drug Administration v. Brown & Williamson Tobacco Corp.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 31 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “All prescription drugs marketed in this country must first receive FDA approval. Manufacturers of new drugs must submit a new drug application (NDA) to the FDA that demonstrates the drug’s effectiveness and safety for its intended use. The 1962 Food, Drug and Cosmetics Act (FDCA) established this avenue for pioneer drugs, with the core objective of ensuring that drugs are both safe and effective; the FDA has codified the NDA regulations at 21 C.F.R. Part 314. New drug approval requires, among other deliverables, the results of successful clinical trials and labeling that accurately portrays the benefits and risks of the drug, as indicated by those trials and other data.”
    1 later decision quote this exact passage · from the majority
  2. “In this ease, unless the law would somehow harness liability onto name brand manufacturers for all failure-to-warn claims, preemption in this case would leave Demahy without a remedy. Yet “[i]f Congress had intended to deprive [Demahy] of a long available form of compensation, it surely would have expressed that intent more clearly.” To hold otherwise would leave us with the bizarre conclusion that Congress intended to implicitly deprive a plaintiff whose doctor prescribes a generic drug of any remedy, while ... that same plaintiff would have a state-law claim had she only demanded a name brand drug instead.”
    1 later decision quote this exact passage · from the majority
  3. “develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to FDA,”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.